FDA Officials Announce Precautionary Pause on Johnson and Johnson Vaccine Rollout

Dr. Janet Woodcock, M.D., Acting Chairperson of the U.S. Food and Drug Administration, said that the temporary pause is being put in place in order for further research and information to be gathered on rare blood clotting that has resulted in 6 patients out of nearly 7 million patients that have been injected with the Johnson & Johnson COVID-19 vaccine so far.

Dr. Peter Marks, M.D., Ph.D., Director of the FDA Center for Biologics Evaluation and Research, explained that the rare blood clot, known as cerebral venous sinus thrombosis, combined with low blood platelet levels in women ages 18-48, showing symptoms in patients within 13-16 days of vaccination.

Stay up to date with our videos by subscribing to our channel: https://www.youtube.com/user/CivicCenterTV15?sub_confirmation=1.
Visit our website for more information on the Megacast and Coronavirus: https://civiccentertv.michigandigital.com/
Follow us ⬇ ⬇
• https://www.youtube.com/user/CivicCenterTV15
• https://www.facebook.com/civiccentertv15/
• https://twitter.com/CivicCenterTV
• https://www.instagram.com/civiccentertv/